ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus(MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. Source
No articles found.
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Level Therapy is a platform that provides treatment tools and video access to lice...
Level Therapy is a platform that provides treat...
The ONLY patented, drug free, saline free, all natural, DAILY nasal hygiene wash, ...
The ONLY patented, drug free, saline free, all ...
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...
Gossamer Bio is a clinical-stage biopharmaceuti...
China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company based in T...
China SXT Pharmaceuticals, Inc. is an innovativ...
Verrica Pharmaceuticals Inc. is an innovative clinical-stage medical dermatology c...
Verrica Pharmaceuticals Inc. is an innovative c...
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the develop...
Aridis Pharmaceuticals, Inc. is a biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.